Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy.
Waasdorp M, Florquin S, Duitman J, Spek CA.
Waasdorp M, et al. Among authors: duitman j.
FASEB J. 2019 Oct;33(10):10966-10972. doi: 10.1096/fj.201900516R. Epub 2019 Jul 9.
FASEB J. 2019.
PMID: 31287960
This is in contrast to the therapeutic potential of vorapaxar in type 1 diabetes-induced nephropathy, highlighting the importance of disease-dependent treatment modalities.-Waasdorp, M., Florquin, S., Duitman, J., Spek, C. A. Pharmacological PAR-1 inhibition reduces …
This is in contrast to the therapeutic potential of vorapaxar in type 1 diabetes-induced nephropathy, highlighting the importance of disease …